The Histopathological Findings of Operated Tumors of the Parathyroid Glands and Patient Data: A Single Centre Experience by Ivan Feldi et al.
SEEMEDJ 2020, VOL 4, NO. 2 Histopathological Findings of Operated Tumors of the Parathyroid Glands 
113 Southeastern European Medical Journal, 2020; 4(2) 
 
Original article 
The Histopathological Findings of Operated Tumors of the 
Parathyroid Glands and Patient Data: A Single Centre Experience 1 
Ivan Feldi *1,2, Ana Jurić 1, Ksenija Marjanović 1,3, Hrvoje Mihalj 1,4, Tatjana Bačun 1,5  
1 Faculty of Medicine, Osijek, Croatia 
2 Department of Internal Medicine, General County Hospital Našice, Našice, Croatia 
3 Clinical Department of Pathology and Forensic Medicine, University Hospital Centre Osijek, Osijek, Croatia 
4 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Centre Osijek, Osijek, 
Croatia 
5 Department of Endocrinology, University Hospital Centre Osijek, Osijek, Croatia 
 
*Corresponding author: Ivan Feldi, ivanfeldi2@gmail.com 
 
Received: Mar 4, 2020; revised version accepted: May 22, 2020; published: Nov 12, 2020 
  
KEYWORDS: parathyroid glands, primary hyperparathyroidism, histopathology, staining and labeling 
 
Abstract 
Introduction: Parathyroid proliferative disorders include adenoma, hyperplasia and carcinoma. 
Adenoma and hyperplasia are more commonly found in women, while carcinoma, which is very rare, 
is equally common in both sexes. The aim of this study was to analyze parathyroid tumors location 
and histopathology and to compare differences between the sexes. Tumors were surgically removed 
at the University Hospital Centre Osijek between 2016 and 2019. 
Patients and Methods: Patients of both sexes who underwent parathyroidectomy for parathyroid 
tumor at the University Hospital Centre Osijek between 2016 and 2019 were included in the study. 
Parathyroid tumor samples were histologically analyzed, and their size and histopathology were 
noted. Existing documentation on patients with parathyroid tumor was used. Analyses were done on 
archived histologic material stained with hematoxylin and eosin. 
Results: Overall, 19 samples of parathyroid tumor were included in this study. Tumors of the 
parathyroid glands were most commonly localized on the lower left parathyroid (8 cases, 42%), and 
least commonly on the upper right parathyroid (2 cases, 11%). The most common disorder was 
adenoma (11 cases, 58%), followed by hyperplasia, while no cases of cancer were diagnosed. Women 
underwent tumor operations more frequently than men (17 versus 2 cases). There was no correlation 
between histopathology of parathyroid tumor and sex (Fisher’s exact test, p = 1) or between tumor 
location and sex (Fisher’s exact test, p = 1). 
Conclusion: The most common locations of tumors of the parathyroid glands were the inferior 
glands; the most common location was the left inferior parathyroid gland and the most common 
disorder was adenoma. Women were operated on more frequently than men.  
(Feldi I, Jurić A, Marjanović K, Mihalj H, Bačun T. The Histopathological Findings of Operated Tumors 
of the Parathyroid Glands and Patient Data: A Single Centre Experience. SEEMEDJ 2020; 4(2); 113-120) 
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Introduction 
Parathyroid glands are 4 nodular structures 
located behind every pole of the thyroid gland. 
They are separated from thyroid gland tissue by 
a fibrous capsule (1). Their size is mostly around 
5 x 3 x 1 mm, and they weigh up to 50 mg (2). On 
rare occasions, the number of parathyroid 
glands can vary from 1 to 12 parathyroid glands 
(3). Due to embryonic development, inferior 
parathyroid glands are most frequently located 
ectopically. Common ectopic locations are 
within the thymus, the mediastinum and the 
thyroid gland, but they are also rarely found 
within the vagus nerve, the pharynx and the 
esophagus (4). The main function of parathyroid 
glands is calcium homeostasis. Parathyroid 
hormone increases serum calcium by increasing 
renal tubular reabsorption of calcium, bone 
resorption and by indirectly increasing vitamin D 
levels, which leads to increased intestinal 
calcium absorption. Parathyroid hormone 
excretion is regulated by ionized calcium levels, 
extracellular phosphate levels and vitamin D (5).  
Chief cells, adipocytes and oxyphil cells make 
up the parathyroid gland parenchyma. Chief 
cells produce and secrete parathyroid hormone 
(6). Oxyphil cell function is not fully understood. 
They are considered to secrete parathyroid 
hormone in secondary parathyroid hyperplasia 
(7). Hematoxylin and eosin stain is used to 
observe parathyroid gland structure, while 
immunochemistry is used to identify molecular 
markers (8).  
Parathyroid gland dysfunction can have 
different causes. Increased secretion of 
parathyroid hormone from at least one 
parathyroid gland leads to primary 
hyperparathyroidism. It is mostly caused by a 
single adenoma, but can be caused by multiple 
adenoma, hypertrophy of all 4 parathyroid 
glands, and rarely by carcinoma (9). Secondary 
hyperparathyroidism is a condition of 
parathyroid hormone oversecretion in response 
to abnormally low calcium in the blood due to 
other pathological processes, such as kidney 
failure, gastrointestinal malabsorption, or 
vitamin D deficiency. Parathyroid hyperplasia 
caused by prolonged hypocalcemia, which is 
seen mostly in chronic kidney failure, is defined 
as tertiary hyperparathyroidism (10, 11).  
Hypoparathyroidism is a rare disorder that 
occurs after damage to or removal of 
parathyroid glands, for example during 
thyroidectomy (12). Pseudohypoparathyroidism 
occurs when the body, and especially the 
kidneys, develops resistance to the parathyroid 
hormone (13).  
  Parathyroid proliferative disorders 
include adenoma, hyperplasia and carcinoma. 
These usually manifest as primary 
hyperparathyroidism (2). Parathyroid adenoma 
usually occurs between the ages of 50 and 70. 
Microadenomas usually do not have a capsule. 
Larger adenomas have a thin fibrous capsule 
and can have cystic degeneration in the tumor. 
Their average weight is one gram. 
Macroscopically, the adenoma is smooth, soft 
and reddish-brown in color, in contrast to the 
yellow-brown of a normal parathyroid gland (2). 
There may be normal parenchyma of a 
parathyroid gland around the edge. 
Histologically, there is a population of enlarged 
cells, glandular architecture with secretions, 
atrophy or compression of parathyroid gland 
tissue (14, 15). Parathyroid hyperplasia usually 
occurs as a result of calcium deficiency, mostly 
due to chronic kidney disease. All 4 parathyroid 
glands are enlarged. In certain cases where 
glands are unevenly enlarged, they may be 
mistaken for adenoma. Resection will not 
resolve the problem in such case (2). 
Histologically, there is parenchymal fat 
accumulation and nodular distribution of chief 
and oxyphil cells (14, 15). 
Parathyroid carcinoma is mostly seen in middle-
aged patients. Risk factors include hereditary 
syndromes such as MEN 1 and MEN 2 (multiple 
endocrine neoplasia type 1 and type 2), familial 
isolated hyperparathyroidism, neck radiation 
and chronic kidney disease. Parathyroid 
hormone and calcium are more increased than 
in adenoma. In addition to the usual 
hypercalcemia symptoms such as nausea, 
vomiting, ulcers, pancreatitis, depression and 
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languor, there are also special symptoms of the 
disease, such as osteoporosis, subperiosteal 
bone resorption and pathological fractures. 
Using ultrasound, carcinoma is identified as a 
mass, usually in inferior poles of the thyroid, with 
a size greater than 3 cm (16, 17). Histologically, 
carcinomas look very similar to adenomas, 
which is why it is difficult to diagnose the disease 
with only histological analysis. Histological 
features of parathyroid carcinoma are thick 
fibrous capsule, adherence to surrounding 
tissue, vascular and capsular invasion, necrosis 
and increased mitotic activity (18). 
Immunohistochemical methods help 
differentiate carcinoma from adenoma. The only 
unequivocal criterion for carcinoma are 
metastases (16). 
 Ultrasound and technetium Tc 99m 
sestamibi scintigraphy scan are most commonly 
used for localization of parathyroid tumor. 
SPECT (single-photon emission computed 
tomography) allows a 3-dimensional image. 
Scintigraphy and SPECT combined have up to 
98% sensitivity for detection of parathyroid 
adenoma (2). Detection of parathyroid glands by 
imaging methods is of no importance for primary 
hyperparathyroidism confirmation. Other 
localization techniques include MRI (magnetic 
resonance imaging), CT (computerized 
tomography) and venous parathyroid hormone 
sampling (19).  
 Parathyroidectomy is the only definitive 
treatment of primary hyperparathyroidism. 
Observation and pharmacological therapy are 
less effective and less cost-effective than 
surgery, even in asymptomatic patients (19 - 21). 
According to the Guidelines of the American 
Association of Endocrine Surgeons, 
parathyroidectomy is indicated in all patients 
with symptomatic primary hyperparathyroidism; 
when the serum calcium level is more than 1 
mg/dL (0,25 mmol/L) above normal, regardless 
of whether objective symptoms are present or 
absent; when there is objective evidence of 
renal involvement, including silent 
nephrolithiasis, nephrocalcinosis, hypercalciuria, 
or impaired renal function; in patients with 
primary hyperparathyroidism and osteoporosis; 
when primary hyperparathyroidism is diagnosed 
in patients aged 50 or younger; in patients with 
parathyroid cancer; in patients who are unable or 
unwilling to comply with observation protocols; 
in patients with neurocognitive and/or 
neuropsychiatric symptoms that are attributable 
to primary hyperparathyroidism. Many different 
surgical methods to streamline 
parathyroidectomy and reduce the risk of 
complications have been developed; they are 
collectively termed minimally invasive 
parathyroidectomy (MIP). The most commonly 
used auxiliary method that significantly 
increases surgery success is intraoperative 
parathyroid hormone measurement (IPM). If, 
during minimally invasive parathyroidectomy, 
intraoperative parathyroid hormone 
measurement indicates residual hypersecreting 
tissue, conversion to bilateral exploration (BE) is 
necessary. Minimally invasive 
parathyroidectomy has the most success with 
solitary adenoma (19). Preventive measures and 
routine monitoring of serum calcium, creatinine 
and bone density are recommended in 
asymptomatic patients that do not meet the 
criteria for surgery (22). 
 The aim of this cross-sectional study with 
historical records was to investigate parathyroid 
tumors that were surgically removed at the 
University Hospital Centre Osijek between 
January 2016 and March 2019. The aim was also 
to review tumor location and histopathology and 
to compare differences between sexes. 
Patients and Methods  
Patients of both sexes who underwent 
parathyroidectomy for parathyroid tumor at the 
University Hospital Centre Osijek between 
January 2016 and March 2019 were included in 
the study. Data were obtained for 19 patients. In 
the Clinical Department of Pathology and 
Forensic Medicine, parathyroid tumor samples 
were histologically analyzed; their size and level 
of histopathological tumor differentiation were 
noted. Existing documentation on patients with 
parathyroid tumor of the Clinical Department of 
Pathology and Forensic Medicine and the 
Department of Maxillofacial Surgery was used. 
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Analysis was done on archived histologic 
material stained with hematoxylin and eosin. 
Approval of the institutional ethical committee 
for this study was obtained from Faculty of 
Medicine Osijek. 
Statistical analysis 
Statistical analysis was done using MedCalc 
Statistical Software version 18.9. Normal 
distribution of variables was tested using the 
Kolmogorov-Smirnov test. Comparisons 
between nominal variables due to the small 
number of samples were made using Fisher’s 
exact test. Alfa = 0.05 was set as the level of 
statistical significance. 
Results 
Data were obtained for 19 patients diagnosed 
with parathyroid tumor. In regard to 
histopathology, the studied sample included 
only adenoma and hyperplasia.  
Women underwent parathyroid tumor 
operations more often than men. Of total of 19 
samples, there were 2 (11%) male samples, and 
17 (89%) female samples.  

















Female 5 (26%) 8 (42%) 2 (11%) 2 (11%)  p = 1 * 
Male 1 (5%) 0 0 1 (5%) 
Total 6 (31%) 8 (42%) 2 (11%) 3 (16%)  
* Fisher’s exact test 
Parathyroid tumor location was observed. Table 
1 shows that parathyroid tumors were 
predominantly located on inferior parathyroid 
glands (14 cases, 74%) in comparison with 
superior parathyroid glands (5 cases, 26%). The 
most common location of the tumor was the left 
inferior parathyroid (8 cases, 42%). There were 6 
cases (31%) of right inferior, 3 cases (16%) of left 
superior and 2 cases (11%) of right superior 
parathyroid gland involvement. 
Of the 2 obtained samples of parathyroid tumor 
in men, one was located on the right inferior and 
one on the left superior parathyroid gland. In 
regard to histopathology, one sample was of 
hyperplasia, and the other was of parathyroid 
adenoma.
Table 2. Distribution of parathyroid gland tumor in both sexes by histopathological diagnosis 





Female 10 (53%) 3 (16%) 4 (21%) p = 1 * 
Male 1 (5%) 1 (5%) 0 
Total 11 (58%) 4 (21%) 4 (21%)  
* Fisher’s exact test 
In our research, we examined the distribution of 
parathyroid tumor by histopathological 
diagnosis. The most common parathyroid tumor 
was adenoma. In regard to histopathology, 11 
samples (58%) were determined as adenoma, 4 
samples (21%) as hyperplasia and 4 samples 
(21%) as undetermined disorders of parathyroid 
tissue (Table 2). In four cases termed as 
“undetermined disorders of parathyroid tissue”, 
due to damaged samples, it was not clear 
whether the tissue histopathology matched 
adenoma or hyperplasia.  
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Although women exhibited more adenoma 
compared to hyperplasia than men, there is no 
correlation between histopathology of 
parathyroid tumor and sex (Fisher’s exact test, p 
= 1). Likewise, even though there were more 
inferior parathyroid tumors in regard to superior 
in women when compared to men, there is also 
no correlation between tumor location and sex 
(Fisher’s exact test, p = 1). Statistical analysis is 
not valid because the male data sample was 
small. 
Discussion 
Parathyroid tumors include adenoma, 
hyperplasia and carcinoma. They most often 
present as primary hyperparathyroidism. 
Parathyroidectomy is the only definitive 
treatment. From 1925, when Felix Mandl 
performed the first successful 
parathyroidectomy in Vienna, many surgical 
techniques have been developed that have 
become less and less invasive (23). Minimally 
invasive parathyroidectomy is a relatively new 
technique that is used increasingly commonly in 
parathyroid adenoma treatment. Its success 
depends on imaging of the tumor. Ultrasound, 
technetium Tc 99m sestamibi scintigraphy scan, 
and intraoperative parathyroid hormone 
measurement can aid the success of the 
operation. The most common parathyroid tumor 
locations are inferior parathyroid glands, with 
frequency of occurrence from 70 to 86.7% (24 - 
26). In our study, tumor was likewise most 
commonly located on inferior parathyroid 
glands. According to our study, the most 
common parathyroid tumor location was the left 
inferior parathyroid gland, which was also the 
case in El-Hady’s and Usta’s studies (24, 25). 
Minimally invasive parathyroidectomy 
decreases the risk of postoperative 
hypocalcemia, the length of procedure, the 
length of hospital stay and overall treatment 
cost (27). Primary hyperparathyroidism is more 
often found in women (10). In the conducted 
study, women were also more affected by 
parathyroid tumors.  
The most common parathyroid gland tumor is 
adenoma (80-85%), which is followed by 
hyperplasia (15%), and carcinoma, which is 
extremely rare (2). In our study, a similar 
distribution was seen, but there were no cases 
of carcinoma. Depending on the literature, 
carcinoma represents from under 1% to 5% of 
cases of parathyroid tumor (28-30). Diagnosing 
carcinoma is not simple. There are no special 
clinical manifestations and histology is 
ambiguous. Clinical manifestations can be more 
extreme than with other causes of primary 
hyperparathyroidism (16). Atypical parathyroid 
adenoma or parathyroid neoplasm of uncertain 
malignant potential is a special histological 
entity that does not meet all the criteria for 
carcinoma. Its course is more benign, it is less 
aggressive than parathyroid carcinoma, and it 
has a greater 5-year survival rate (31, 32). In the 
same period, three patients had 
parathyroidectomy for multi-gland hyperplasia 
due to secondary hyperparathyroidism (results 
not shown). All three of them had chronic kidney 
failure and were on a hemodialysis program. 
In the conducted study, primary 
hyperparathyroidism was the most common 
clinical diagnosis, followed by secondary 
hyperparathyroidism. Primary 
hyperparathyroidism occurs in over 2% of the 
population older than 55 (33). It is usually caused 
by solitary adenoma, but can also be caused by 
multiple adenomas, hypertrophy and 
carcinoma. Risk factors include neck radiation, 
lithium intake or hereditary factors such as MEN 
1 and MEN 2 syndromes (8). It manifests as 
hypercalcemia with increased or normal level of 
parathyroid hormone. Patients usually have no 
symptoms, but in symptomatic patients, it 
manifests as fatigue, weakness, depression, 
gastroesophageal reflux and bone pain. In the 
advanced stage, it can manifest as skeletal 
disease, nephrolithiasis and cardiovascular 
disease (10).  
In secondary hyperparathyroidism, there is 
normal parathyroid hormone secretion as a 
response to chronically low calcium levels. Low 
calcium levels are caused by malabsorption, 
vitamin D deficiency, kidney failure and taking 
certain medication, such as thiazide diuretics. 
Serum calcium level is low or normal, and 
parathyroid hormone level is normal. In tertiary 
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hyperparathyroidism, after an initial stimulus, 
parathyroid glands become autonomous, and 
parathyroid hormone levels and calcium levels 
resemble primary hyperparathyroidism. Clinical 
symptoms of secondary hyperparathyroidism 
depend on the underlying cause (8, 34). 
Our study did not show a correlation between 
sex and tumor location, or between sex and type 
of tumor. To our knowledge, no study has so far 
analyzed the correlation between sex and tumor 
location. Only 2 male samples were analyzed, 
which was not sufficient for making an adequate 
statistical analysis. Corresponding to the 
correlation between sex and tumor location, it is 
known that adenoma is found 3 times more 
often in women than in men (18, 35). In the study 
by Cvasciuc (36), patients with parathyroid 
adenoma were predominantly female, and there 
was a similar female-to-male ratio in regard to 
adenoma and hyperplasia. Carcinoma affects 
both sexes equally commonly (16).  
It is important to note that these are data 
collected from patients who were subjected to 
parathyroidectomy at our University Hospital 
Centre. Not all patients with primary or 
secondary hyperparathyroidism are operated 
on, so this study can in no way present the 
prevalence of hyperparathyroidism in the area 
gravitating to the University Hospital Centre in 
Osijek. The sizes of tumors in samples from this 
area were 0.7-2.2 cm (results not shown). 
  The main limitation of the study was its 
small sample, which is probably the reason why 
there were no cases of carcinoma. If the sample 
were larger, carcinoma frequency could have 
been assessed. The aim of this study was to 
review the possible connection between sex 
and parathyroid tumor histopathology or 
location, but only 2 male samples were 
obtained, which was not sufficient for making a 
statistical analysis. 
 To conclude, the study shows that 
women are operated on for tumors of the 
parathyroid gland more often, which most 
commonly manifest as adenomas. Parathyroid 
tumors were more frequently located in inferior 
parathyroid glands, and the most common 
location was the left inferior parathyroid gland. 
Acknowledgement. None. 
Disclosure 
Funding. No specific funding was received for 
this study. 
Competing interests. None to declare. 
i
References 
1. Taterra D, Wong LM, Vikse J, Sanna B, Pękala 
P, Walocha J, Cirocchi R, Tomaszewski K, Henry 
BM. The prevalence and anatomy of parathyroid 
glands: a meta-analysis with implications for 
parathyroid surgery. Langenbecks Arch Surg. 
2019; 404(1):63-70. 
2. Wieneke JA, Smith A. Parathyroid adenoma. 
Head Neck Pathol. 2008; 2(4):305–308. 
doi:10.1007/s12105-008-0088-8 
3. Caron NR, Sturgeon C, Clark OH. Persistent 
and recurrent hyperparathyroidism. Curr Treat 
Options Oncol. 2004; 5(4):335-45. 
4. Miura D. Ectopic parathyroid tumor in the 
sternohyoid muscles: supernumerary gland in a 
patient with MEN type 1. J. Bone Miner. Res. 2005; 
20(8):1478-9. 
5. Schappacher-Tilp G, Cherif A, Fuertinger DH, 
Bushinsky D, Kotanko P. A mathematical model 
of parathyroid gland biology. Physiol Rep. 2019; 
7(7):e14045. 
6. Byrd C, Kwartowitz G. Cancer, Parathyroid. 
[Updated 2019 Feb 24]. In: StatPearls [Internet]. 
Treasure Island (FL): StatPearls Publishing; 2020 
Jan-. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK5190
38/ 
7. Tanaka Y, Funahashi H, Imai T, Seo H, 
Tominaga Y, Takagi H. Oxyphil cell function in 
secondary parathyroid hyperplasia. Nephron. 
1996;73(4):580-6. 
SEEMEDJ 2020, VOL 4, NO. 2 Histopathological Findings of Operated Tumors of the Parathyroid Glands 
119 Southeastern European Medical Journal, 2020; 4(2) 
 
8. Brown MB, Limaiem F. Histology, Parathyroid 
Gland. [Updated 2019 Sep 20]. In: StatPearls 
[Internet]. Treasure Island (FL): StatPearls 
Publishing; 2020 Jan-. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK5465
96/ 
9. Baloch ZW, LiVolsi VA. Pathology of the 
parathyroid glands in hyperparathyroidism. 
Semin Diagn Pathol. 2013;30(3):165-77. 
10. Fraser WD. Hyperparathyroidism. Lancet. 
2009; 374(9684):145-58. 
11. Khan M, Sharma S. Physiology, Parathyroid 
Hormone (PTH) [Updated 2019 Apr 25]. In: 
StatPearls [Internet]. Treasure Island (FL): 
StatPearls Publishing; 2020 Jan-. 
12. Mannstadt M, Bilezikian JP, Thakker RV, 
Hannan FM, Clarke BL, Rejnmark L, Mitchell DM, 
Vokes TJ, Winer KK, Shoback DM. 
Hypoparathyroidism. Nat Rev Dis Primers. 2017; 
3:17080. 
13. Linglart A, Levine MA, Jüppner H. 
Pseudohypoparathyroidism. Endocrinol. Metab. 
Clin. North Am. 2018;47(4):865-888. 
14. Rosai J. Parathyroid glands. Rosai and 
Ackerman's Surgical Pathology. 10th ed., Vol. 1. 
Missouri: Mosby Elsevier; 2012. p. 573-7. 
15. Thompson LD. Benign and malignant 
neoplasms of the parathyroid glands. In: 
Goldblum JR, editor. Endocrine Pathology. 2nd 
ed. London: Churchill Livingstone; 2006. p. 157-
81. 
16. McClenaghan F, Qureshi YA. Parathyroid 
cancer. Gland Surg 2015; 4(4):329-338. doi: 
10.3978/j.issn.2227-684X.2015.05.09 
17. Goswamy J, Lei M, Simo R. Parathyroid 
carcinoma. Curr Opin Otolaryngol Head Neck 
Surg. 2016; 24(2):155-62. 
18. Wolfe SA, Sharma S. Parathyroid Adenoma. 
[Updated 2019 Mar 4]. In: StatPearls [Internet]. 




19. Wilhelm SM, Wang TS, Ruan DT, Lee  JA , Asa 
SL, Duh  Q-Y, Doherty  GM, Herrera MF, Pasieka  
JL, Perrier ND, Silverberg SJ, Solórzano CC, 
Sturgeon C, Tublin ME, Udelsman R, Carty SE. 
The American Association of Endocrine 
Surgeons Guidelines for Definitive Management 
of Primary Hyperparathyroidism. JAMA Surg. 
2016; 151(10):959–968. 
doi:10.1001/jamasurg.2016.2310 
20. Zanocco K, Angelos P, Sturgeon C. Cost-
effectiveness analysis of parathyroidectomy for 
asymptomatic primary hyperparathyroidism. 
Surgery. 2006; 140(6):874-881. 
21. Zanocco KA, Wu JX, Yeh MW. 
Parathyroidectomy for asymptomatic primary 
hyperparathyroidism: A revised cost-
effectiveness analysis incorporating fracture risk 
reduction. Surgery 2017; 161:16. 
22. Bilezikian JP, Brandi ML, Eastell R, Silverberg 
SJ, Udelsman R, Marcocci C, Potts JT Jr. 
Guidelines for the management of 
asymptomatic primary hyperparathyroidism: 
summary statement from the Fourth 
International Workshop. J Clin Endocrinol Metab 
2014; 99:3561. 
23. Mandl F. Therapeutic attempt for osteitis 
fibrosa generalisata via the excision of 
parathyroid tumours. Wien Klin Wochenschr. 
1925; 38:1,343–1,344. 
24. El-Hady HA, Radwan HS. Focused 
parathyroidectomy for single parathyroid 
adenoma: a clinical account of 20 patients. 
Electron Physician. 2018; 10(6):6974–6980. 
Published 2018 Jun 25. doi:10.19082/6974 
25. Usta A, Alhan E, Cinel A, Türkyılmaz S, Erem 
C. A 20-year study on 190 patients with primary 
hyperparathyroidism in a developing country: 
Turkey experience. Int Surg. 2015; 100(4):648–
655. doi:10.9738/INTSURG-D-14-00094.1 
26. Afzal A, Gauhar TM, Butt WT, Khawaja AA, 
Azim KM. Management of hyperparathyroidism: 
a five year surgical experience. J Pak Med Assoc. 
2011; 61(12):1194–8. 
27. Udelsman R. Six hundred fifty-six 
consecutive explorations for primary 
SEEMEDJ 2020, VOL 4, NO. 2 Histopathological Findings of Operated Tumors of the Parathyroid Glands 
120 Southeastern European Medical Journal, 2020; 4(2) 
 
hyperparathyroidism. Ann Surg. 2002; 
235(5):665–672. doi:10.1097/00000658-
200205000-00008 
28. Marococci C, Cetani F, Rubin MR, Silverberg 
SJ, Pinchera A, Bilezikian JP. Parathyroid 
carcinoma. J Bone Miner Res 2008; 23:1869-80. 
29. Obara T, Fujimoto Y. Diagnosis and treatment 
of patients with parathyroid carcinoma: An 
update and review. World J Surg. 1991; 15:738–
744. 
30. Favia G, Lumachi F, Polistina F, D'Amico DF. 
Parathyroid carcinoma: Sixteen new cases and 
suggestions for correct management. World J 
Surg. 1998; 22:1225–1230. 
31. Ramaswamy AS, Vijitha T, Kumarguru BN, 
Mahalingashetti PB. Atypical parathyroid 
adenoma. Indian J Pathol Microbiol 2017; 60:99-
101 
32. Christakis I, Bussaidy N, Clarke C, 
Kwatampora LJ, Warneke CL, Silva  AM, 
Williams MD, Gardner Grubbs E, Lee  JE, Perrier 
ND. Differentiating Atypical Parathyroid 
Neoplasm from Parathyroid Cancer. Ann Surg 
Oncol 2016; 23:2889. 
33. Madkhali T, Alhefdhi A, Chen H, Elfenbein D. 
Primary hyperparathyroidism. Ulus Cerrahi Derg. 
2016; 32(1):58-66. 
34. Portillo MR, Rodríguez-Ortiz ME. Secondary 
Hyperparthyroidism: Pathogenesis, Diagnosis, 
Preventive and Therapeutic Strategies. Rev 
Endocr Metab Disord. 2017; 18(1):79-95. 
35. Edafe O, Collins EE, Ubhi CS, 
Balasubramanian SP. Current predictive models 
do not accurately differentiate between single 
and multigland disease in primary 
hyperparathyroidism: a retrospective cohort 
study of two endocrine surgery units. Ann R Coll 
Surg Engl. 2018; 100(2):140-145. 
36. Cvasciuc IT, Ismail W, Lansdown M. Primary 
hyperparathyroidism- strategy for multigland 
disease in the era of SPECT-CT. Acta Endocrinol 
(Buchar). 2017;13(1):1–6. doi:10.4183/aeb.2017.1 
 
 
i Author contribution. Acquisition of data: Feldi I, Jurić 
A, Marjanović K, Mihalj H, Bačun T 
Administrative, technical or logistic support: Feldi I, 
Jurić A, Marjanović K, Mihalj H, Bačun T 
Analysis and interpretation of data: Feldi I, Jurić A, 
Marjanović K, Mihalj H, Bačun T 
Conception and design: Feldi I, Jurić A, Marjanović K, 
Mihalj H, Bačun T 
Critical revision of the article for important intellectual 
content: Feldi I, Jurić A, Marjanović K, Mihalj H, Bačun 
T 
Drafting of the article: Feldi I, Jurić A, Marjanović K, 
Mihalj H, Bačun T 
Final approval of the article: Feldi I, Jurić A, Marjanović 
K, Mihalj H, Bačun T 
Guarantor of the study: Feldi I, Jurić A, Marjanović K, 
Mihalj H, Bačun T 
Obtaining funding: Feldi I, Jurić A, Marjanović K, Mihalj 
H, Bačun T 
Provision of study materials or patients; Feldi I, Jurić 
A, Marjanović K, Mihalj H, Bačun T 
Statistical expertise: Feldi I, Jurić A, Marjanović K, 
Mihalj H, Bačun T 
Other: Feldi I, Jurić A, Marjanović K, Mihalj H, Bačun T 
